News

Article

New Insight: Phase 2 BEHOLD Study and UBX1325 for DME, Live at AAO 2023

Author(s):

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Episode Highlights

0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion

On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema (DME), based on the 48-week results from the phase 2 BEHOLD study.

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify, Apple Podcasts, and YouTube. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

Keep an eye out for more from New Insight!

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Wei Zhang, MD, PhD: Naltrexone’s GI, Liver Safety for Alcohol Use Disorder Treatment
© 2024 MJH Life Sciences

All rights reserved.